Patent · US Active

Anti-ceramide antibodies

US10450385B2 · kind B2 · utility

1Cited by

2References

4Claims

0Family size

Assignees

Memorial Sloan Kettering Cancer Center · US
CERAMIDE THERAPEUTICS · US

Inventors

Jimmy Andrew Rotolo · New York, US
Richard Kolesnick · New York, US

Key dates

Filing date	Aug 7, 2015
Grant date	Oct 22, 2019
Priority date	—
Expiry date	Mar 9, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.